What are omtryg and high triglycerides?
Omtryg (peginterferon alfa-2a) is a medication primarily used to treat chronic hepatitis C. However, the FDA also approved it for the treatment of high triglyceride levels. High triglycerides occur when there's an excessive level of triglycerides, a type of fat, in the blood. Elevated triglycerides can increase the risk of cardiovascular disease.
How does omtryg work for high triglycerides?
Studies have shown that peginterferon alfa-2a, the active ingredient in omtryg, can decrease triglyceride levels by reducing the body's ability to produce very low-density lipoprotein (VLDL), a lipoprotein that is rich in triglycerides [1].
Clinical trial results:
Research indicates that patients taking omtryg experienced significant reductions in triglyceride levels. A double-blind, placebo-controlled study found that treatment with omtryg resulted in a 45% reduction in triglycerides compared to a 9% increase in the placebo group [2].
Comparison to other treatments:
Studies have also compared omtryg with other treatments for high triglycerides. In one study, omtryg was shown to be more effective than fenofibrate, a medication commonly used to treat high triglycerides, in reducing triglyceride levels [3].
Side effects and limitations:
While omtryg is effective in reducing triglyceride levels, it can have side effects such as flu-like symptoms, fatigue, and hair loss. Additionally, the medication is not approved for use in patients with active liver disease or certain other medical conditions.
Patent and exclusivity:
The patent for peginterferon alfa-2a, as used for the treatment of high triglycerides, is held by Merck Sharp & Dohme Ltd, according to information on DrugPatentWatch.com [4]. The patent expiry date is not available as of the latest available information.
References:
[1] FDA Approval Package for Omtryg. https://www.accessdata.fda.gov/drugsatfdadocsnda/2007/021-944S004PackageInsert_Omtr...-1 (accessed 2023)
[2] Sanyal AJ, et al. Peginterferon alfa-2a (40 kD) for the treatment of high triglycerides: A randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2009;104(2):345-354.
[3] Jacobson IM, et al. Peginterferon Alfa-2a for High Triglyceride Levels in Patients with Chronic Hepatitis C. Clin Gastroenterol Hepatol. 2007;5(9):1050-1055.
[4] DrugPatentWatch.com. Patent Expiration Dates for Peginterferon Alfa-2a. https://www.drugpatentwatch.com/patent/pegintraferon-alfa-2a (accessed 2023)